Cornerstone Investment Partners LLC Takes $44.50 Million Position in IQVIA Holdings Inc. $IQV

Cornerstone Investment Partners LLC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 282,378 shares of the medical research company’s stock, valued at approximately $44,500,000. IQVIA comprises about 2.0% of Cornerstone Investment Partners LLC’s investment portfolio, making the stock its 28th largest position. Cornerstone Investment Partners LLC owned 0.17% of IQVIA as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of IQV. Verdence Capital Advisors LLC purchased a new stake in shares of IQVIA during the second quarter worth $3,612,000. Patton Fund Management Inc. acquired a new position in IQVIA during the second quarter worth about $231,000. Heritage Investors Management Corp grew its stake in IQVIA by 10.5% during the 2nd quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock valued at $16,500,000 after acquiring an additional 9,909 shares in the last quarter. Private Advisor Group LLC lifted its stake in IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after purchasing an additional 566 shares in the last quarter. Finally, Nordea Investment Management AB boosted its holdings in shares of IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after purchasing an additional 606,391 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of analyst reports. Stifel Nicolaus lifted their price objective on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Truist Financial reaffirmed a “buy” rating and issued a $265.00 target price (up from $235.00) on shares of IQVIA in a research note on Wednesday, October 29th. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Finally, Mizuho boosted their target price on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $239.94.

IQVIA Trading Up 0.6%

Shares of IQV stock opened at $211.29 on Friday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $225.91. The firm has a market cap of $35.98 billion, a PE ratio of 28.98, a price-to-earnings-growth ratio of 2.35 and a beta of 1.34. The company has a 50-day moving average of $198.98 and a two-hundred day moving average of $175.59. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same period in the prior year, the business posted $2.84 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.